hart_vol

Jimmy Berbée, PhD

Career: Dr. Jimmy F.P. Berbée is currently Contract Research Coordinator and Assistant Professor at the Department of Endocrinology at the LUMC. He performed his PhD at TNO-Biosciences and subsequently became a postdoctoral researcher at the Department of Endocrinology at the LUMC. After postdoctoral research fellowships at Sanquin Amsterdam and Lübeck University (Germany), he returned as an Assistant Professor at the Department of Endocrinology at the LUMC. Moreover, he holds a postdoctoral research position at the University of Patras (Greece).
During his career he was awarded several prices from e.g. the Dutch Atherosclerosis Society (DAS; Young Investigator Award), Arteriosclerosis, Thrombosis and Vascular Biology (ATVB; New Investigator Award), and European Atherosclerosis Society (EAS; Best Poster Award). Awarded grants include Netherlands Foundation Grant for Cardiovascular Excellence (NFCVE; 100 k€), Bontius Fellowship (40 k€), Postdoctoral Research support by the General Secretariat for Research and Technology from Greece (GSRT; 150 k€), and Lung Foundation grant (250 k€).

Academic Research focus: His academic research focusses mainly on the (pathophysiological) role of lipid/glucose metabolism and inflammation in obesity, diabetes and atherosclerosis development.
Current projects include:
-The effect of brown adipose tissue activation on dyslipidemia and atherosclerosis.
-Metabolic and immunologic consequences of bone marrow transplantation.
-The role of C-type Lectin receptors in (hyperglycemia-induced) atherosclerosis.
-The effect of monocytes/macrophage training by microorganisms on atherosclerosis.
-The effect of chronic kidney disease on lipid metabolism and atherosclerosis

Contract Research Coordinator of Leiden Metabolic Research Services (LMRS): He coordinates the Leiden Metabolic Research Services (LMRS), a large contract research program at the department of Endocrinology of the LUMC. This program mainly focusses on metabolic aspects of cardiovascular disease, including:
-Dyslipidemia
-Energy metabolism, with a specific focus on the role of brown adipose tissue
-Obesity
-Insulin resistance
-Nonalcoholic steatohepatitis (NASH) and Nonalcoholic fatty liver disease (NAFLD)
-Atherosclerosis
-Intestinal microbiota

Within this field of expertise we offer custom-made drug and dietary intervention studies in among others our unique dyslipidemic and atherosclerosis-prone APOE*3-Leiden.CETP transgenic mouse model.

Key benefits of APOE*3-Leiden.CETP mice:
•Dyslipidemia, with plasma lipid levels easily titrated to desired levels.
•Diet-induced atherosclerosis, driven by both cholesterol and inflammation.
•Brown fat activation with reduction of obesity, dyslipidemia and atherosclerosis.
•Validated model that responds in a similar manner as humans to:
-Lipid-lowering strategies: statins, PCSK9 inhibitors, fibrates
-HDL-raising strategies: CETP inhibitors, niacin
-Anti-obesity strategies: brown fat activators including CB1R blockers
-Anti-diabetic strategies: metformin, GLP-1 analogues